These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 10146863)
1. Low-dosage epoetin in maintenance haemodialysis: costs and quality-of-life improvement. Harris DC Pharmacoeconomics; 1994 Jan; 5(1):18-28. PubMed ID: 10146863 [TBL] [Abstract][Full Text] [Related]
2. A decision analysis comparing three dosage regimens of subcutaneous epoetin in continuous ambulatory peritoneal dialysis. Piccoli A; Puggia RM; Fusaro M; Favaro E; Pillon L Pharmacoeconomics; 1995 May; 7(5):444-56. PubMed ID: 10155331 [TBL] [Abstract][Full Text] [Related]
3. Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life. Whittington R; Barradell LB; Benfield P Pharmacoeconomics; 1993 Jan; 3(1):45-82. PubMed ID: 10146987 [TBL] [Abstract][Full Text] [Related]
4. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Dunn CJ; Markham A Drugs; 1996 Feb; 51(2):299-318. PubMed ID: 8808169 [TBL] [Abstract][Full Text] [Related]
5. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Faulds D; Sorkin EM Drugs; 1989 Dec; 38(6):863-99. PubMed ID: 2693045 [TBL] [Abstract][Full Text] [Related]
6. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients. Dunn CJ; Wagstaff AJ Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784 [TBL] [Abstract][Full Text] [Related]
7. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries. Leese B; Hutton J; Maynard A Pharmacoeconomics; 1992 May; 1(5):346-56. PubMed ID: 10146999 [TBL] [Abstract][Full Text] [Related]
8. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Markham A; Bryson HM Drugs; 1995 Feb; 49(2):232-54. PubMed ID: 7729331 [TBL] [Abstract][Full Text] [Related]
9. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Collins AJ Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii2-6. PubMed ID: 12819293 [TBL] [Abstract][Full Text] [Related]
10. Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer. Cheer SM; Wagstaff AJ Drugs; 2004; 64(3):323-46. PubMed ID: 14871172 [TBL] [Abstract][Full Text] [Related]
11. Optimal use of epoetin-alpha in the anaemia of chronic renal failure. Ifudu O BioDrugs; 1999 Mar; 11(3):175-83. PubMed ID: 18031128 [TBL] [Abstract][Full Text] [Related]
12. Potential cost savings of erythropoietin administration in end-stage renal disease. Hynes DM; Stroupe KT; Greer JW; Reda DJ; Frankenfield DL; Kaufman JS; Henderson WG; Owen WF; Rocco MV; Wish JB; Kang J; Feussner JR Am J Med; 2002 Feb; 112(3):169-75. PubMed ID: 11893342 [TBL] [Abstract][Full Text] [Related]
13. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. Deicher R; Hörl WH Drugs; 2004; 64(5):499-509. PubMed ID: 14977387 [TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer. Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437 [TBL] [Abstract][Full Text] [Related]
15. Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients. Courtney AE; McNamee PT; Maxwell AP Nephron Clin Pract; 2007; 107(1):c14-9. PubMed ID: 17664890 [TBL] [Abstract][Full Text] [Related]
16. Is there a role for adjuvant therapy in patients being treated with epoetin? Hörl WH Nephrol Dial Transplant; 1999; 14 Suppl 2():50-60. PubMed ID: 10334668 [TBL] [Abstract][Full Text] [Related]